The growth of tiny broker tellurian organs, joined with rarely supportive mass spectrometry technologies, could one day change a approach new drugs and poisonous agents are studied.
“By building this ‘homo minutus,’ we are stepping over a need for animal or Petri plate testing: There are outrageous advantages in building drug and toxicity research systems that can impersonate a response of tangible tellurian organs,” pronounced Rashi Iyer, a comparison scientist during Los Alamos National Laboratory.
ATHENA, a Advanced Tissue-engineered Human Ectypal Network Analyzer plan team, is impending a full formation of 4 tellurian organ constructs — liver, heart, lung and kidney — any organ member is about a distance of a smartphone screen, and a whole ATHENA “body” of companion viscera will fit orderly on a desk.
A new video accessible from the Los Alamos National Laboratory YouTube channel updates a ATHENA plan as it starts to confederate a several organ systems into a singular system.
Some 40 percent of pharmaceuticals destroy their clinical trials and there are thousands of chemicals whose effects on humans are simply unknown. Providing a realistic, cost-effective and fast screening complement such as ATHENA with high-throughput capabilities could yield vital advantages to a medical field, screening some-more accurately and charity a larger possibility of clinical hearing success.
ATHENA is saved by a Defense Threat Reduction Agency (DTRA) and is a partnership of Los Alamos National Laboratory, Harvard University, Vanderbilt University, Charité Universitätsmedizin, Berlin, Germany, CFD Research Coporation, and a University of California San Francisco.